Novo Ends Phase III Kidney Disease Trial, Incurs More Than $800M Q2 Impairment Loss
Novo Ends Phase III Kidney Disease Trial, Incurs More Than $800M Q2 Impairment Loss 6/27/2024
Novo Ends Phase III Kidney Disease Trial, Incurs More Than $800M Q2 Impairment Loss 6/27/2024